Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections
Nicole F. Maranchick, Jessica Webber, Mohammad H. Alshaer, Timothy W. Felton, Charles A. Peloquin · 2023
Read Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections by Nicole F. Maranchick, Jessica Webber, Mohammad H. Alshaer, Timothy W. Felton, Charles A. Peloquin (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10740680.txt.
Description
Maranchick and co-authors ask whether hitting the right drug dose keeps bacteria from learning resistance mid-treatment. Reviewing 256 patients with Gram-negative infections at a Florida hospital, they linked measured drug levels to later shifts in how much drug the bacteria could withstand. Three beta-lactam drugs and 628 isolates were in play, Pseudomonas the commonest foe.
One exposure measure stood out. Patients whose daily drug exposure reached at least 494 times the kill threshold saw less new resistance, by either a small or a doubling yardstick, and spent fewer days on treatment. Pseudomonas infections, by contrast, carried six to seven times the odds of growing resistant. The authors nominate the 494 target for prospective testing.
Catalog record
| CREATOR | Nicole F. Maranchick, Jessica Webber, Mohammad H. Alshaer, Timothy W. Felton, Charles A. Peloquin |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |